Paperonium

HIV prevention · Lancet HIV · 2025

Summary’s numbers: adding an injection cuts an HIV program’s benefit by two-thirds. Its table: triples it.

Healthy years savedThe summaryIts own table18,400With injection56,400With injection56,400Without injection18,400Without injection
Healthy years savedThe summaryIts own table18,400With injection56,400With injection56,400Without injection18,400Without injection

The summary versus its own table, per 10 million adults each year

The paper says

The paper simulates an HIV-prevention program with and without a preventive injection. Its summary (the short overview at the top) says that per 10 million adults each year, the program saves 18,400 healthy years with the injection and 56,400 without, compared with no program.

Its own data show

The paper’s table prints the same two numbers the other way round: 56,400 with the injection, 18,400 without. The summary’s own cost of $234 per healthy year fits only the table: the injection version costs $13.2 million a year more than no program, and $13.2 million ÷ 56,400 = $234; ÷ 18,400 would give $717.

Studies like this count benefit in “healthy years”: years of healthy life that illness or early death would otherwise take away. The rest of the paper, including its results and conclusion, agrees with its table. But anyone reading only the summary would think adding the injection cuts the program’s benefit by two-thirds, when it roughly triples it.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Dynamic choice HIV prevention with long-acting injectable cabotegravir pre-exposure prophylaxis in east, central, southern, and west Africa: a cost-effectiveness modelling analysis · Lancet HIV (2025) · doi:10.1016/S2352-3018(25)00169-9